3-Methyl-1-[2-(2-methylpropoxy)ethoxy]butane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Methyl-1-[2-(2-methylpropoxy)ethoxy]butane
• 英文别名: 3-methyl-1-[2-(2-methylpropoxy)ethoxy]butane
• 化学式: C₁₁H₂₄O₂
• 分子量: 188.31
• InChiKey: XLIFQVWCLCVOPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT
  申请人：Bertrand Philippe

  公开号：US20140219925A1

  公开（公告）日：2014-08-07

  Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.

  新型聚合物纳米载体或颗粒及其作为药物和/或诊断试剂的用途。
• US20140343123A1
  申请人：——

  公开号：US20140343123A1

  公开（公告）日：2014-11-20
• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126719A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126718A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126720A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.